Tove Olafsen

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas
    Tove Olafsen
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    J Nucl Med 50:1500-8. 2009
  2. pmc Antibody vectors for imaging
    Tove Olafsen
    UCLA Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA
    Semin Nucl Med 40:167-81. 2010
  3. ncbi request reprint Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment
    Tove Olafsen
    Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, 700 Westwood Plaza, Los Angeles, California 90095, USA
    Nat Protoc 1:2048-60. 2006
  4. ncbi request reprint Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody
    Tove Olafsen
    Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine at University of California, Los Angeles, CA 90095, USA
    J Immunother 30:396-405. 2007
  5. ncbi request reprint Protein targeting constructs in alpha therapy
    Tove Olafsen
    Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Curr Radiopharm 4:197-213. 2011
  6. ncbi request reprint Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging
    Tove Olafsen
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California at Los Angeles, 90095, USA
    Cancer Res 65:5907-16. 2005
  7. pmc ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies)
    Tove Olafsen
    Department of Molecular and Medical Pharmacology, UCLA Crump Institute for Molecular Imaging, Los Angeles, CA 90095, USA
    Protein Eng Des Sel 23:243-9. 2010
  8. ncbi request reprint Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting
    Tove Olafsen
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 700 Westwood Plaza, Los Angeles, CA 90095, USA
    Protein Eng Des Sel 17:315-23. 2004
  9. ncbi request reprint Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy
    Vania Kenanova
    Division of Molecular Biology, Beckman Research Institute of the City of Hope, Department of Radioimmunotherapy, Duarte, CA, USA
    Cancer Res 67:718-26. 2007
  10. pmc Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors
    Jeffrey V Leyton
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA
    Clin Cancer Res 14:7488-96. 2008

Collaborators

Detail Information

Publications36

  1. pmc Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas
    Tove Olafsen
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    J Nucl Med 50:1500-8. 2009
    ..To provide more sensitive, tumor-specific PET imaging of NHL, we sought to develop PET agents targeting CD20...
  2. pmc Antibody vectors for imaging
    Tove Olafsen
    UCLA Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA
    Semin Nucl Med 40:167-81. 2010
    ..The preclinical data presented are compelling, and it is evident that antibody-based molecular imaging tracers will play an important future role in the diagnosis and management of cancer and other diseases...
  3. ncbi request reprint Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment
    Tove Olafsen
    Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, 700 Westwood Plaza, Los Angeles, California 90095, USA
    Nat Protoc 1:2048-60. 2006
    ..The time frame for completing the procedure is about 6 months, provided that no complications are encountered...
  4. ncbi request reprint Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody
    Tove Olafsen
    Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine at University of California, Los Angeles, CA 90095, USA
    J Immunother 30:396-405. 2007
    ..These data support further development of hu1G8 anti-PSCA antibody for targeted imaging and therapy for tumors of urogenital origin...
  5. ncbi request reprint Protein targeting constructs in alpha therapy
    Tove Olafsen
    Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Curr Radiopharm 4:197-213. 2011
    ..e. diabody) and tetramer, CH2 domain deleted antibody fragments); other protein targeting constructs such as affibodies and peptides as well as liposomal delivery...
  6. ncbi request reprint Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging
    Tove Olafsen
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California at Los Angeles, 90095, USA
    Cancer Res 65:5907-16. 2005
    ..1 +/- 1.5% ID/g). Thus, by manipulating the size and format of anti-p185(HER2) antibody fragments, the kidney activity was reduced and high or low expression of p185HER2 in xenografts could be distinguished by microPET imaging...
  7. pmc ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies)
    Tove Olafsen
    Department of Molecular and Medical Pharmacology, UCLA Crump Institute for Molecular Imaging, Los Angeles, CA 90095, USA
    Protein Eng Des Sel 23:243-9. 2010
    ..Specific tumor targeting and high contrast images were achieved with the anti-CD20 diabodies. These agents extend the repertoire of reagents that can potentially be used to improve detection of low-grade lymphomas...
  8. ncbi request reprint Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting
    Tove Olafsen
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 700 Westwood Plaza, Los Angeles, CA 90095, USA
    Protein Eng Des Sel 17:315-23. 2004
    ..62 h) was similar. Thus, minibodies with different specificities display similar pharmacokinetics, while tumor uptake may vary depending on the antigen-antibody system...
  9. ncbi request reprint Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy
    Vania Kenanova
    Division of Molecular Biology, Beckman Research Institute of the City of Hope, Department of Radioimmunotherapy, Duarte, CA, USA
    Cancer Res 67:718-26. 2007
    ..Finally, the 125I/111In biodistribution data allowed for dose estimations, which suggest the 131I-labeled scFv-Fc H310A/H435Q as a promising candidate for radioimmunotherapy...
  10. pmc Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors
    Jeffrey V Leyton
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA
    Clin Cancer Res 14:7488-96. 2008
    ..In this study, the 2B3 minibody (an 80-kDa engineered antibody fragment) has been produced for rapid targeting and imaging...
  11. ncbi request reprint Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications
    Tove Olafsen
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095
    Protein Eng Des Sel 17:21-7. 2004
    ..This format will provide a versatile platform for targeting a variety of agents to CEA-positive tumors...
  12. ncbi request reprint Fusion of Gaussia luciferase to an engineered anti-carcinoembryonic antigen (CEA) antibody for in vivo optical imaging
    Katy M Venisnik
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Mol Imaging Biol 9:267-77. 2007
    ..4% ID/g) at 21 hours. Although further optimization of this fusion protein may be needed to improve in vivo performance, the diabody-GLDelta15 is a promising optical imaging probe for tumor detection in vivo...
  13. pmc Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors
    Jeffrey V Leyton
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Protein Eng Des Sel 22:209-16. 2009
    ..Although the higher affinity bm2B3-Db8 demonstrated improved tumor retention at later time points (20 h), it did not improve tumor targeting or imaging compared with p2B3-Db8 at 12 h...
  14. pmc Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins
    Vania E Kenanova
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, California NanoSystems Institute, University of California, Los Angeles, 570 Westwood Plaza, CA 90095 1770, USA
    Protein Eng Des Sel 23:789-98. 2010
    ..H464 appears to be most crucial for FcRn binding (greatest reduction in MRT), followed by H510 and H535. By mutating the DIII scaffold, we can dial serum kinetics for imaging or therapy applications...
  15. doi request reprint Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer
    Mark D Girgis
    Department of Surgery, UCLA, Los Angeles, California 90095, USA
    J Surg Res 170:169-78. 2011
    ..Our goal was to develop and characterize the anti-CA19-9 diabody fragment and determine its ability to provide antigen specific imaging of pancreas cancer...
  16. ncbi request reprint Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments
    Vania Kenanova
    Division of Molecular Biology, Beckman Research Institute of the City of Hope, Duarte, CA, USA
    Cancer Res 65:622-31. 2005
    ..Thus, attenuating the Fc-FcRn interaction provides a way of controlling the antibody fragment serum half-life without compromising expression and tumor targeting...
  17. doi request reprint Engineered antibody fragments with infinite affinity as reporter genes for PET imaging
    Liu H Wei
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA
    J Nucl Med 49:1828-35. 2008
    ..The objective of the present study was to evaluate a new approach for reporter gene imaging based on cell surface expression of antibody fragments that can irreversibly bind to radiometal chelates...
  18. pmc An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors
    Eric J Lepin
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Eur J Nucl Med Mol Imaging 37:1529-38. 2010
    ..However, the humanization and antibody fragment reformatting decreased its apparent affinity. Here, we sought to evaluate PET imaging contrast with affinity matured minibodies...
  19. pmc Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2
    Shannon J Sirk
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Bioconjug Chem 19:2527-34. 2008
    ..Conjugates retained both specificity and fluorescence, demonstrating the successful expansion of the CysDb repertoire to new targets and to new site-specific conjugation possibilities...
  20. doi request reprint Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo
    Richard Tavare
    Crump Institute for Molecular Imaging and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, Howard Hughes Medical Institute, Department of Microbiology, Immunology, and Molecular Genetics, and Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095
    Proc Natl Acad Sci U S A 111:1108-13. 2014
    ..Both (64)Cu-radiolabeled Mbs produced high-contrast immuno-PET images 4 h postinjection and showed specific uptake in the spleen and lymph nodes of antigen-positive mice. ..
  21. pmc Positron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments
    Maoyong Fu
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Mol Imaging Biol 15:68-78. 2013
    ....
  22. pmc Recombinant carcinoembryonic antigen as a reporter gene for molecular imaging
    Vania Kenanova
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, 700 Westwood Plaza, Los Angeles, CA 90095, USA
    Eur J Nucl Med Mol Imaging 36:104-14. 2009
    ..We have developed a reporter gene based on carcinoembryonic antigen (CEA), a human protein with limited normal tissue expression...
  23. ncbi request reprint Bifunctional antibody-Renilla luciferase fusion protein for in vivo optical detection of tumors
    Katy M Venisnik
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Protein Eng Des Sel 19:453-60. 2006
    ....
  24. pmc Cys-diabody quantum dot conjugates (immunoQdots) for cancer marker detection
    Bhaswati Barat
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Bioconjug Chem 20:1474-81. 2009
    ....
  25. pmc Evaluation of two internalizing carcinoembryonic antigen reporter genes for molecular imaging
    Bhaswati Barat
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1770, USA
    Mol Imaging Biol 13:526-35. 2011
    ..The objective of this article is to develop internalizing positron emission tomography (PET) reporter genes for tracking genetically modified T cells in vivo...
  26. doi request reprint Antibodies for molecular imaging of cancer
    Anna M Wu
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Cancer J 14:191-7. 2008
    ..Antibody imaging can provide a sensitive, noninvasive means for molecular characterization of cell surface phenotype in vivo, which can in turn guide diagnosis, prognosis, therapy selection, and monitoring of treatment in cancer...
  27. pmc Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment
    Mark D Girgis
    Department of Surgery, UCLA, 10833 LeConte Ave, Rm 54 140, Los Angeles, CA 90095, USA
    EJNMMI Res 1:24. 2011
    ..abstract:..
  28. doi request reprint Fc engineering: serum half-life modulation through FcRn binding
    Tove Olafsen
    Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Methods Mol Biol 907:537-56. 2012
    ..Here, we describe site-specific mutagenesis of Fc residues in a scFv-Fc fusion protein, as well as the mammalian production, purification, characterization, and the in vivo pharmacokinetics of these antibody fragments...
  29. doi request reprint ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging
    Tove Olafsen
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 570 Westwood Plaza, CNSI 4335, Box 951770, Los Angeles, CA 90095 1770, USA
    Tumour Biol 33:669-77. 2012
    ..This approach can be broadly applied to antibodies targeting cell surface biomarkers for molecular imaging of tumors and should be highly translatable for clinical use...
  30. pmc CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer
    Mark D Girgis
    Department of Surgery, UCLA, 10833 LeConte Avenue, Rm 54 140, Los Angeles, CA 90095, USA
    Int J Mol Imaging 2011:834515. 2011
    ..Conclusion. We show in vivo targeting of our antigen positive xenograft with a radiolabeled anti-CA19-9 antibody. These data demonstrate the potential to achieve anti-CA19-9 antibody based positron emission tomography of pancreas cancer...
  31. pmc Unexpected expression pattern for glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPIHBP1) in mouse tissues revealed by positron emission tomography scanning
    Tove Olafsen
    Department of Molecular and Medical Pharmacology, California NanoSystems Institute, Los Angeles, California 90095, USA
    J Biol Chem 285:39239-48. 2010
    ..In support of this concept, lung LPL levels were significantly lower in Gpihbp1(-/-) mice than in Gpihbp1(+/+) mice. In addition, Lpl(-/-) mice expressing human LPL exclusively in muscle contained high levels of human LPL in the lung...
  32. pmc Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT
    Sepideh Afshar
    Department of Microbiology, Immunology, and Molecular Genetics, UCLA, 247 BSRB, 615 Charles E, Young East, Los Angeles, 90095, USA
    J Exp Clin Cancer Res 28:147. 2009
    ..abstract:..
  33. pmc The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry
    Kouki Morizono
    Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
    Cell Host Microbe 9:286-98. 2011
    ..These results reveal an alternative molecular mechanism of viral entry that can broaden host range and enhance infectivity of enveloped viruses...
  34. pmc Levels of murine, but not human, CXCL13 are greatly elevated in NOD-SCID mice bearing the AIDS-associated Burkitt lymphoma cell line, 2F7
    Daniel P Widney
    Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 8:e72414. 2013
    ..This mouse model may be useful for future studies on the interactions of the innate immune system and AIDS-BL tumor cells, as well as for the assessment of potential tumor biomarkers for this disease. ..
  35. ncbi request reprint PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody
    Weibo Cai
    Molecular Imaging Program at Stanford, Department of Radiology, Stanford University School of Medicine, Stanford, California 94305 5484, USA
    J Nucl Med 48:304-10. 2007
    ..66 diabody, a genetically engineered noncovalent dimer of single-chain variable fragments, for small-animal PET imaging of CEA expression in xenograft-bearing mice...
  36. ncbi request reprint Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody
    Lin Li
    Division of Immunology, Beckman Research Institute of the City of Hope, Duarte, California 91010, USA
    Bioconjug Chem 13:985-95. 2002
    ..Furthermore, we demonstrated a role for the attachment chemistry to the epsilon-amino group of the lysine on the magnitude of kidney uptake...